<DOC>
<DOCNO>EP-0626966</DOCNO> 
<TEXT>
<INVENTION-TITLE>
3-SUBSTITUTED IMIDAZO(1,5-A)QUINOXALINES AND QUINAZOLINES WITH CNS ACTIVITY.
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K31495	A61K31495	A61K31505	A61K31505	A61P2500	A61P2500	A61P2508	A61P2520	C07D48700	C07D48704	C07D48714	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61K	A61P	A61P	A61P	A61P	C07D	C07D	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61K31	A61K31	A61P25	A61P25	A61P25	A61P25	C07D487	C07D487	C07D487	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
A 4-oxoimidazo(1,5-a)quinoxaline of formula (I), a 5-oxoimadazo(1,5-a)quinoxaline of formula (II), a diimidazoquinazoline of formula (III) or a pharmaceutically acceptable salt thereof, wherein R3 is (a), (b), (c), (d). The R-groups and "Aryl" are as defined herein. The compounds are useful in the treatment of central nervous system disorders associated with the benzodiazepine receptors in a subject in need of such treatment comprising administering to the subject a therapeutically-effective amount of formula (I), (II) or (III) compound for alleviation of such disorder. Typically, the compound of formula (I), (II) or (III) is administered in the form of a pharmaceutical composition comprising a pharmaceutically-acceptable carrier or diluent.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
UPJOHN CO
</APPLICANT-NAME>
<APPLICANT-NAME>
THE UPJOHN COMPANY
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
HESTER JACKSON B JR
</INVENTOR-NAME>
<INVENTOR-NAME>
JACOBSEN ERIC JON
</INVENTOR-NAME>
<INVENTOR-NAME>
SKALETZKY LOUIS L
</INVENTOR-NAME>
<INVENTOR-NAME>
TEN BRINK RUTH ELIZABETH
</INVENTOR-NAME>
<INVENTOR-NAME>
HESTER, JACKSON, B., JR.
</INVENTOR-NAME>
<INVENTOR-NAME>
JACOBSEN, ERIC, JON
</INVENTOR-NAME>
<INVENTOR-NAME>
SKALETZKY, LOUIS, L.
</INVENTOR-NAME>
<INVENTOR-NAME>
TEN BRINK, RUTH, ELIZABETH
</INVENTOR-NAME>
</INVENTORS>
<DESCRIPTION>
-subst1 tuted Imidazo ( l , 5-a)qui noxal 1 nes and qui nazol i nes with CNS activity BACKGROUND OF THE INVENTION1. Field of the Invention This invention is imidazo(l,5-a)quinoxalines and iπ-idazo(l,5-a)quinazolines with aryl, heteroaryl, ketone and thioketone at position 3, which are uselful for treating anxiety, sleep disorders, panic disorders, convulsive disorders and/or depression.2. Description of the Related Art European Patent 225,013 (U.S. Patent 4,774,245; 4,771,051; 4,886,797; 4,880,799) disclose imidazo(l,5-a)quinoxaline and 4-oxoimidazo(l,5-a)quinoxalines compounds, useful as anxiolytic and hypnotic agents, having an ester or oxadiazole substituent at the 3-position.European Patent 202,441-A discloses imidazo(l,5-a)quinazoline compounds useful as anxiolytic and hypnotic agents, containing an oxadiazole at the 3-position and halogen, nitrile, methyl and trifluoromethyl groups at the 6-position.European Patent 320,136-A discloses 4-oxoimidazo(l,5-a)quinoxaline compounds useful as anxiolytic and hypnotic agents, containing oxadiazole or ester substituents at the 3-position and hydrogen or halogen substituents at the 6-position. The ring atom at position 6 may be carbon or nitrogen.European Patent 283,162 (US 4,902,686; 4,873,244) discloses 4-oxoimidazo(l,5- a)quinoxalines and 5-oxoimidazo(l,5-a)quinazolines having anticonvulsant and anxiolytic activity, with oxadiazoles, esters, and amides at position 3.European Patent 368,652 (US 4,999,353) discloses 4-oxoimidazoquinoxalines useful as anxiolytics and hypnotics with an oxadiazole at position 3 and tert-butyl at position 5. European Patent Application 344,943A (US 5,075,304) discloses imidazo[l,5- a]quinoxalin-4-ones with methyl at N5 useful as anticonvulsants, anxiolytics and hypnotics. South African Patent 8701,535, assigned to The Upjohn Co., discloses 5- oxoimidazo(l,5-a)quinazolines having anxiolytic activity, with oxadiazole and ester substituents at position 3 and Cl at position 6.Japanese Patent 89027074 discloses imidazobenzodiazepines useful as anticonvulsants and anxiolytics containing an oxadiazole at the 3-position. U.S. Patent 4,440,929 discloses 4-thio, 4-imino, 4-hydroxyimino, 4-oxoimidazo(l,5- a)quinoxaline compounds containing nitrile, carboxaldehyde, carboxyϊic acid, ester, amide and methylalcohol substituents at the 3-posiuon and H, alkyl, alkenyl, alkynyl, aryl, aralkyl, hydroxy, and alkanoyl at the 5-position.U.S. Patent 4,866,065 discloses imidazo(l,5-a)thieno(2,3-e)pyrimidines useful as anticonvulsant, hypnotics, etc.
</DESCRIPTION>
<CLAIMS>
WHAT IS CLAIMED:
1. A 4-oxoimidazo(l,5-a)quinoxaline of formula (I)
or a pharmaceutically acceptable salt thereof, wherein R
3
 is
Aryl -COAryl — CSR
n
(a) 0 (c) (d) wherein "Aryl" is as defined in Chart D and is substituted with R
14
 and R
16
 as indicated;
R
5
 is Cι.
8
 alkyl, C
3
.
7
 cycloalkyl, C
M
 alkyl-C
3
.
7
 cycloalkyl, C
2
.
6
 alkenyl (optionally substituted with C^ alkyl), (CH
2
)
n
-Aryl, (CH
2
)
m
N(R
12
)
2
, or (CH
2
)
m
OR
n
 and n is 0-4 and m is 2- 4;
R
6
 and R
7
 are independently H, F, Cl, Br, I, C C
4
 alkyl, ON, N0
2
, CF
3
, 


 C0
2
R
π
, CON(R
12
)
2
, (CH
2
)
π
N(R
12
)
2
, (OCH
2
CH
2
)
n
-OH or NHCOR
n
;
R
8
 is O, S, NH, NCH
3
, N(CH
2
)
n
-C
3
.
7
 cycloalkyl, -CCR,^ or NCHO;
R
9
 is H, C-.
4
 alkyl, phenyl (except that only one Rg can be phenyl or t-butyl at the same time);
R
u
 is H, C
j
.
6
 alkyl, C
3
.
7
 cycloalkyl, C
M
 alkyl-C
3
.
7
 cycloalkyl, or -(CH
2
)
π
-Aryl;
R
I2
 is independently H, C
j
.
6
 alkyl, C
3
-C
7
 cycloalkyl, -C-
^
, alkyl-C
3
.
7
 cycloalkyl, phenyl, or taken together with the attached nitrogen atom to form a heterocyclic ring -N*(CH
2
)
p
R
13
 (CH
2
)
0
* where the * indicates the atoms bonded to each other to form said heterocyclic ring, where p is 2-5 and o is 0-3;
R
13
 is O, S, CO, CH
2
, NR
16
;
R
M
 is independently H, F, Cl, Br, I, CN, N0
2
, OCOR
π
, (CH
2
)
π
CF
3
, C
M
 alkyl, G
j
- cycloalkyl, C
M
 alkyl-C
3
.
7
 cycloalkyl, (CH
2
)
n
N(R
12
)
2
, (CH
2
)
n
OR„, N(R
12
)COR
n
, (CH
2
)
n
C0
2
R
n
, (CH
2
)
n
SR
H
, S0
2
N(R
I2
)
2
, COR
π
, phenyl (optionally substituted with F, Cl, Br, OCH
3
, CH
3
 or CF
3
); and
Rι
6
 is H, C
M
 alkyl, Cj-C, cycloalkyl, CHO, C alkyl-C
3
.
7
 cycloalkyl. CO-R
π
. 


 R
i6
 is H, C
M
 alkyl, Gj- cycloalkyl, CHO, C
1
 alkyl-C
3.7
 cycloalkyl, CO-R
π
.
1. A 4-oxoimidazo(l,5-a)quinoxaline (I) according to claim 1 where R
3
 is selected from the group consisting of benzoxazol-2-yl, thiazol-2-yl, oxazoIin-2-yl, l,2,4-trϊazol-3-y! and a phenyl optionally substituted with one -CH
3
, -OCH
3
 or -F.
3. A 4-oxoimϊdazo(l,5-a)quinoxaIine (I) according to claim 1 where R
3
 is selected from the group consisting of 4-fluorophenyl, thiazol-2-yI and benzoxazol-2-yl.
4. A 4-oxoimidazo(l,5-a)quinoxaline (I) according to claim 1 where R
5
 is C
r
C
4
 alkyl-
5- A 4-oxoimϊdazo(I,5-a)quinoxaIine (I) according to claim 1 where Rg and R
7
 are independently -H, -F, -Cl, -CF
3
 or -CH
3
.
6. A 4-oxoimidazo(l,5-a)quinoxaline (I) according to claim 1 where the 4-oxoimidazo (l,5-a)quinoxaline (I) is a) 4,5-dihydro-5-isopropyl-3-(4-methoxyphenyl)-4-oxoimidazo(l,5-a)quinoxaline, b) 7-fluoro-4,5-dihydro-5-isopropyl-4-oxo-3-phenyIimidazo(l,5-a)quinoxaline, c) 3-(4-fluorophenyl)-4,5-dihydro-5-isopropyl-4-oxoimidazo(l,5-a)quinoxaline, d) 7-fluoro-3-(4-fluorophenyI)*^,5-dihydro-5-isopropyl-4-oxoimidazo(l,5-a)quinoxaline, e) 6-c oro-3-(fluorophenyl)-4,5-dmydro-5-isopropyl-4-oxoimidazo(l,5-a)quinoxaline, f) 4,5-dihydro-5-isopropyl-4-oxo-3-phenylimidazo(l ,5-a)quinoxaline, g) 3-(2-furyl)-4,5-dihydro-5-isopropyl-4~oxoimidazo(l ,5-a)quinoxaline, h) 4,5-dihydro-5-isopropyl-3-(4-methylphenyl)-4-oxoimidazo(l,5-a)quinoxaIine, i) 3-(benzoxazoI-2-yl)-4,5-dihydro-5-isopropyl-4-oxoimidazo(l ,5-a)quinoxaline, j) 3-(benzoxazol-2-yl)-7-fluoro-4,5-dihydro-5-isopropyl-4-oxoimidazo(l,5-a)quinoxaline, k) 4,5-dihydro-5-isopropyl-3-(oxazolin-2-yl)-4-oxoimidazo(l,5-a)quinoxaline,
1) 4,5-dihydro-5-isopropyI- -oxo-3-(tWazol-2-yl)imidazo(l,5-a)quinoxaline, m) 4,5-dihydro-5-isopropyI-4-oxo-3-(l,2,4-triazol-3-yl)imidazo(l,5-a)quinoxaline, n) 4,5-dmydro-5-isopropyl-3-(5-memyl-l,2,4-triazol-3-yl)-4-oxoimidazo(l,5-a)quinoxaIine, o) 4,5-dihydro-5-isopropyl-3-(l-methyl-l,2,4-triazol-3-yl)-4-oxoimidazo(l,5-a)quinoxaline, p) 4,5-dmydro-5-isopropyl-3-(2-methyl-l,2,4-triazol-3-yl)-4-oxoimidazo(l,5-a)quinoxaline, q) 3-(3-fluorophenyl)-4,5-dihydro-5-isopropyl-4-oxoimidazo(l,5-a)quinoxaline, r) 7-Huoro-3-(3-fluorophenyl)-4,5-dihydro-5-isopropyl-4-oxoimidazo(l,5-a)quinoxaline, s) 6-chloro-3-(3-fluorophenyl)-4,5-dihydro-5-isopropyl-4-oxoimidazo(l,5-a)quinoxaline, t) 7-fiuoro-4^-dihydro-5-isopropyl-3-(4-methoxyphenyl)-4-oxoimidazo(l,5-a)quinoxaline, 


u) 6-chloro-4,5-dihydro-5-isopropyl-3-(4-methoxyphenyl)-4-oxoimidazo(l,5-a)quinoxaline, v) 6-chloro-4,5-dihydro-5-isopropyl-3-(3-methoxyphenyl)-4-oxoimidazo(l,5-a)quinoxaline, w) 7-fluoro-4,5-dihydro-5-isopropyl-4-oxo-3-(3-trifluoromethylphenyl)imidazo
(l,5-a)quinoxaline, x) 4,5-dihydro-5-isopropyl-3-(3-methoxyphenyl)-4-oxoimidazo(l,5-a)quinoxaline, y) 4,5-dihydro-5-isopropyl-4-oxo-3-(3-trifluoromethylphenyl)imidazo(l,5-a)quinoxaline, z) 4,5-dihydro-5-isopropyl-3-(4-methoxyphenyl)-6-methyl-4-oxoimidazo(l,5-a)quinoxaline, aa) 3-(4-fluorophenyl)-4,5-dihydro-5-isopropyl-6-methyl-4-oxoimidazo(l,5-a)quinoxaline, bb) 3-(4-Cyclopropylthiazol-2-yl)-4,5-dihydro-5-isopropyl-4-oxoimidazo(l,5-a)quinoxaline, cc) 3-(4-Cyclopropyloxazol-2-yl)-4,5-dihydro-5-isopropyl-4-oxoimidazo(l,5-a)quinoxaline, or dd) 3-(4-Cyclopropyloxazol-2-yl)-7-fluoro-4,5-dihydro-5-isopropyl-4-oxoimidazo
( 1 ,5-a)quinoxaline.
7. A 5-oxoimidazo(l,5-a)quinazoline of formula (II)
or a pharmaceutically acceptable salt thereof, wherein R
3
 is
— Aryl — COAryl — CSR 11 

CO 00 CO CO
wherein "Aryl" is as defined in Chart D and is substituted with R
I4
 and R
16
 as indicated; R
5
 is Cj-g alkyl, C,.**. cycloalkyl, C alkyl-C
3
.
7
 cycloalkyl, C
2
.
6
 alkenyl (optionally substituted with C*.
3
 alkyl), (CH
2
)
π
-Aryl, (CH
2
)
m
N(R
12
)
2
, or (CHJ.-OR.. and n is 0-4 and m is 2-4; 


 R
5
 and R
7
 are independently H, F, Cl, Br, I, C
r
C
4
 alkyl, ON, N0
2
, CF
3
, (CH^^Ru, C0
2
R
π
, CON(R
12
)
2
, (CH^NOt^, (OCH
2
CH
2
)
π
-OH or NHCOR
π
;
R
8
 is O, S, NH, NCH
3
, N^H^-C^ cycloalkyl, -C(R
<
,)
2
 or NCHO;
R
9
 is H, Cj.
4
 alkyl, phenyl (except that only one R, can be phenyl or t-buty! at the same time);
R
n
 is H, Ci.
6
 alkyl, .*-, cycloalkyl, C
14
 alkyl-C
3
.
7
 cycloalkyl, or -(CH^-Aryl;
R
12
 is independently H, C*^ alkyl, G
j
-C-, cycloalkyl, -C
l
 alkyl-C
3
.
7
 cycloalkyl, phenyl, or taken together with the attached nitrogen atom to form a heterocyclic ring -^(CH^
p
R^ (CH--X* where the * indicates the atoms bonded to each other to form said heterocyclic ring, where p is 2-5 and o is 0-3;
R
13
 is 0, S, CO, CH
2
, NR
16
;
R
14
 is independently H, F, Cl, Br, I, CN, N0
2
, OCOR„, (CH
2
)
π
CF
3
, C
M
 alkyl, C__- - cycloalkyl, C
w
 alkyl-C„ cycloalkyl, (CH
2
)
n
N(R
12
)
2
, (CH
2
)
π
OR
π
, N(R
12
)COR
n
, (CH^CO^, (OH^SRn, S0
2
N(R
I2
)
2
, COR
u
, phenyl (optionally substituted with F, Cl, Br, OCH
3
, CH
3
 or CF
3
); and
R
16
 is H, C
w
 alkyl, -C, cycloalkyl, CHO, C
l
 aIkyI-C
3
.
7
 cycloalkyl, CO-R
u
.
8. A 5-oxoimidazoI(l,5-a)quinazolϊne (H) according to claim 7 where R
3
 is selected from the group consisting of substituted phenyl, benzoxazol-2-yl, thiazol-2-yl, oxazolin-2-yl and 1,2,4- triazol-3-yl.
9. A 5-oxoimidazol(l,5-a)quinazoline (H) according to claim 7 where R
3
 is selected from the group consisting of 4-fiuorophenyl, thiazol-2-yl and benzoxazol-2-yl.
10. A 5-oxoimidazol(l,5-a)quinazoline (H) according to claim 7 where R
5
 is C
r
 alkyl.
11. A 5-oxoimidazol(l,5-a)quinazoline (H) according to claim 7 where Rg and R
7
 are independently -H, -F, -Cl, -CF
3
 or CH
3
.
12. A diimidazoquinazoline of formula (HI)

 or a
*
 pharmaceutically acceptable salt thereof, 


wherein R
3
 is
—Aryl — COAryl — CSR
n
O CO O CO
wherein "Aryl" is as defined in Chart D and is substituted with R
14
 and R
J6
 as indicated;
R
4
 is H, or C
Γ
C
6
 alkyl; R
5
 is H, Cj.
8
 alkyl, C
3
_
7
 cycloalkyl, C alkyl-C
3.7
 cycloalkyl, ^ alkenyl (optionally substituted with C^ alkyl), (CH
2
)
n
-Aryl, (CH
2
)
m
N(R
12
)
2
, or (CH
2
)
m
OR
π
 and n is 0*4 and m is 2-4;
R
6
 and R
7
 are independently H, F, Cl, Br, I, C
r
C
4
 alkyl, ON, N0
2
, CF
3
, (CH^ORn, C0
2
R
π
, CON(R
12
)
2
, (CH
2
)
π
N(R
12
)
2
, (OCH
2
CH
2
)
n
-OH or NHCOR
u
; R
8
 is O, S, NH, NCH
3
, N(CH
2
)
n
-C
3
.
7
 cycloalkyl, -Cfll^ or NCHO;
R
9
 is H, C
M
 alkyl, phenyl (except that only one R, can be phenyl or t-butyl at the same time);
R
n
 is H, Cι.
6
 alkyl, C
3
.
7
 cycloalkyl, C
M
 alkyl-C
3.7
 cycloalkyl, or -(CH
2
)
n
-Aryl;
R
12
 is independently H, C*.
6
 alkyl, C
3
-C-, cycloalkyl, -C
l
 alkyl-C
3
.
7
 cycloalkyl, phenyl, or taken together with the attached nitrogen atom to form a heterocyclic ring -N*(CH
2
) 
p
R
13
 (CH
2
)
0
* where the * indicates the atoms bonded to each other to form said heterocyclic ring, where p is 2-5 and o is 0-3;
R
13
 is O, S, CO, CH
2
, NR
16
;
R
14
 is independently H, F, Cl, Br, I, CN, N0
2
, OCOR
u
, (CH
2
)
n
CF
3
, .
6
 alkyl, - cycloalkyl, C
M
 alkyl-C
3
.
7
 cycloalkyl, (CH
2
)
n
N(R
12
)
2
, (CH
2
)
n
OR
n
, N(R
12
)COR
n
, (CH
2
)
π
C0
2
R
π
, (CH
2
)
n
SR
π
, S0
2
N(R
12
)
2
, COR
n
, phenyl (optionally substituted with F, Cl, Br, OCH
3
, CH
3
 or CF
3
); and
R
16
 is H, C
M
 alkyl, -C, cycloalkyl, CHO, C
M
 alkyl-C
3.7
 cycloalkyl, CO-R
π
.
13. A diimidazoquinazoline (III) according to claim 12 where R
3
 is selected from the group consisting of substituted phenyl, benzoxazol-2-yl, thiazol-2-yl, oxazolin-2-yl and l,2,4-triazol-3- yi-
14. A diimidazoquinazoline (III) according to claim 12 where R
3
 is selected from the group consisting of 4-fluorophenyl, thiazol-2-yl and benzoxazol-2-yl. 


15. A diimidazoquinazoline (HI) according to claim 12 where R
5
 is H or C
r
C
4
 alkyl.
16. A diimidazoquinazoline (HI) according to claim 12 where Rg and R
7
 are independently -H, -F, -Cl, -CF
3
 or CH
3
.
17. A use of a compound of Formula I, II or HI for the preparation of a medicament useful for treating central nervous system disorders associated with the benzodiazepine receptors in a patient in need of such treatment comprising administering to the patient a therapeutically- effective amount of a compound of Formula I, II or HI for alleviation of such disorder. 

</CLAIMS>
</TEXT>
</DOC>
